PRESS RELEASE, 3 April 2022
Kongsberg Beam Technology’s groundbreaking technology in MaMa-K, which initially was designed for proton radiation therapy has been further developed. The MaMa-K will therefore be available for a much larger market including both proton and traditional radiation therapies. The MaMa-K system offers improved accuracy and precision in real-time enabling proton and traditional radiation therapies to reach their full potential.
The intelligent MaMa-K system creates a digital model of the patient with the tumour based on images and with the use of sensors monitoring the organs’ movements. The digital model will provide possibilities for real-time adjustments of the beam during treatment, which will result in decreased irradiation of healthy tissue – and in the end, less side effects for the patients.
The global market for radiation therapy is expected to increase over the next years as the number of cancer patients, unfortunately will rise. With MaMa-K, more patients will benefit from accurate radiation treatment, saving healthy tissue from damage and reducing side effects. This is a major step forward for the entire radiation industry.
“Due to the revised project plan and the government grants, we now have an updated financing roadmap. The ambition is to raise a maximum of NOK 20 million in equity financing. This will bring the company to the position where it becomes an interesting partner for future commercial collaborations.”, says CEO Kerstin Jakobsson.
For further information please contact:
CEO, Kongsberg Beam Technology AS
Phone: +46 705 50 45 40
About Kongsberg Beam Technology
Kongsberg Beam Technology is a MedTech company that develops an advanced system, MaMa-K, for personalised radiation therapy in real-time with better precision and accuracy resulting in less damage to healthy tissue. Kongsberg Beam technology is headquartered in Kongsberg, Norway. For more information, please visit www.kongsbergbeamtech.com.